Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis

Article Abstract:

The drug alendronate appears to prevent bone loss in patients who take corticosteroids. Researchers randomly assigned 477 men and women on corticosteroids to take 5 or 10 milligrams of alendronate or a placebo daily. Bone density at the hip and lumbar spine was measured at one, two, three and four years. Bone density in those taking alendronate increased two percent or more in the spine and one percent or more in the hip. Those taking placebo lost bone density in those areas. Alendronate reduced the risk of vertebral fractures by 40%.

Evaluation, Bones, Prevention, Complications and side effects, Corticosteroids, Adrenocortical hormones, Bone density

---

Ten years' experience with alendronate for osteoporosis in postmenopausal women

Article Abstract:

The results of a multinational randomized, double-blind study, in which postmenopausal women with osteoporosis were treated with alendronate for unto 10 years, are reported. The discontinuation of alendronate resulted in a gradual loss of effect, as measured by bone density and biochemical markers of bone remodeling.

Usage, Patient outcomes, Postmenopausal women

---

Clues for new therapeutics in osteoporosis

Article Abstract:

The findings of Klein et al. are presented. These findings help to understand the pathogenesis of osteoporosis and develop treatments and strategies for prevention.

United States

Similar abstracts:

• Abstracts: The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. Invasive cardiovascular procedures -- optimizing patient safety
• Abstracts: International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis
• Abstracts: Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women
• Abstracts: Improving practice through a system of clinical supervision. Assessing patients' eligibility for fully funded nursing care
• Abstracts: Diabetes research investment in the European Union. After criticism, more modest cancer genome project takes shape

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.